Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: treatment with DIELEN® Protect, treatment with placebo of DIELEN® Protect.
- Who it may be relevant to
- Registry conditions: Irritable Bowel Syndrome. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Irritable bowel syndrome (IBS) affects around 5% of the general population and remains a daily problem in clinicians' practices, with inconsistent efficacy of treatments despite patients' high expectations. Intestinal hyperpermeability and visceral hypersensitivity are the two major components of IBS, and both can disrupt gastrointestinal function and ultimately impair patients' quality of life. Glutamine is a non-essential amino acid that regulates numerous metabolic pathways and plays a key role in the intestine as it is the preferred substrate for enterocytes and immune cells. A decrease in intestinal glutamine synthetase has been found in IBS, suggesting its involvement in the intestinal permeability and visceral hypersensitivity observed in patients. Ex vivo, glutamine is capable of restoring the expression of tight junction proteins in IBS-D patients. Furthermore, glutamine supplementation is capable of reducing abdominal pain and restoring intestinal permeability disorders in a sub-group of patients with intestinal permeability disorders (post-infectious IBS-D). The marine peptides Gabolysat® produced by the Dielen Laboratory have demonstrated their efficacy on intestinal permeability and inflammation in a preclinical model of IBS (Langlois et al. 2023), similar to glutamine supplementation in these animals. The Dielen® Protect product formulated on the basis of the results of this study combines glutamine and Gabolysat® to provide a comfort solution for IBS patients. Our working hypothesis is that patients suffering from moderate or severe IBS could benefit from oral supplementation with DIELEN Protect to improve the symptoms associated with IBS. 100 patients with IBS (according to Rome IV criteria) will be included in our study. All patients will test the treatment for 8 weeks (dielen protect or placebo). The efficacy will be compared between the 2 groups before and after the treatments using validated questionnaires. Therefore, all participants will fill questionnaire before and after 8 weeks of treatments : IBS severity (IBS-SSS), quality of life (GIQLI), Anxiety and depression (HAD), GI symptom related anxiety (VSI), stool frequency and consistancy (BSF scale). Microbiota, metabolomic and short chain fatty acid will be analysed before and after the intervention.
Interventions
- Drug treatment with DIELEN® Protect
treatment with DIELEN® Protect for 8 weeks at a dose of 5 grams, 3x a day - Drug treatment with placebo of DIELEN® Protect
treatment with placebo of DIELEN® Protect for 8 weeks at a dose of 5 grams, 3x a day
Primary outcome measures
- Symptomatic efficacy of DIELEN® Protect supplementation [Time frame: from enrollment up to 8 weeks]
Secondary outcome measures (8)
- impact of DIELEN® Protect on the composition of the intestinal microbiota [Time frame: from enrollment up to 8 weeks]
- Impact of DIELEN® Protect on quality of life [Time frame: from enrollment up to 8 weeks]
- impact of DIELEN® Protect on gastrointestinal related anxiety [Time frame: from enrollment up yto 8 weeks]
- impact of DIELEN® Protect on anxiety and/or depression [Time frame: from enrollment up to 8 weeks]
- impact of DIELEN® Protect on stool frequency [Time frame: from enrollment up to 8 weeks]
- impact of DIELEN® Protect on stool consistency [Time frame: from enrollment up to 8 weeks]
- treatment compliance rate [Time frame: from enrollment up tu 8 weeks]
- Number and severity of adverse reactions [Time frame: from enrollment up to 8 weeks]
Eligibility criteria
Inclusion criteria
- Irritable bowel syndrome according to Rome IV criteria
- Aged between 18 and 75 years
- IBS-SSS > 175 at inclusion
- For women of childbearing age, use of effective contraception (progestins or oestroprogestins or intrauterine device or tubal ligation) for 1 month unless postmenopausal (amenorrhoea of at least 12 months or biologically confirmed diagnosis) or woman who has had a hysterectomy or salpingectomy.
- Irritable bowel syndrome treatments that have been stable for more than one month
- Membership of a social security scheme
- Patient has read and understood the information letter and signed the consent form
Exclusion criteria
- Taking probiotics, food supplements containing glutamine, anti-inflammatory drugs or antibiotics in the month preceding the study.
- Allergy to fish and glutamine
- Known renal insufficiency (Glomerular Filtration Rate (GFR)<30mL/min/1.73m2), known hepatic insufficiency (Prothrombin Time (PT)<70%) or known cardiac disease.
- History of organic digestive disease (coeliac disease, inflammatory bowel disease, abdominal surgery other than appendectomy or cholecystectomy)
- Pregnant women, women in labour or breastfeeding mothers
- Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship
- Patient taking part in another trial / having taken part in another trial within a 4-week period
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
France · 1 center
- CHU de Rouen — Rouen
Identifiers
NCT: NCT07039747 · 2024/0178/HP